To include your compound in the COVID-19 Resource Center, submit it here.

Eureka's ET140202 leads to tumor regression in Phase I for HCC

By Jaime De Leon | Sep 21, 2018 | 4:43 PM GMT

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE